Document:

Supply Agreement

 Exhibit 10.24 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 [ETHICON LOGO] 
 November 9, 2006 
 Advanced BioHealing, Inc. 

10933 N. Torrey Pines Road, Suite 200 
 La Jolla,
CA 92037 
 Attention: Gerald F. Vovis, Ph.D. 
 Dear Dr. Vovis: 
 You have requested us to furnish VICRYLTM brand knitted mesh, product
code VKML (the “Mesh”), to you for use as a raw material by you solely in the manufacture of DERMAGRAFT® by you. Ethicon, Inc., acting by and through its Ethicon Products division (“Ethicon”), is willing to supply the Mesh to
Advanced BioHealing, Inc. (“Advanced BioHealing”) in consideration of the agreements contained in this letter agreement (the “Agreement”). 
 1. Agreements by the Parties. 
 (a) Made by Advanced
BioHealing. Advanced BioHealing represents and warrants that it is relying on its own investigation and judgment, and it is not relying on any representation of Ethicon, concerning the quality, usefulness or other attribute of the Mesh for use
as a raw material or otherwise in the manufacture of DERMAGRAFT®. Advanced BioHealing acknowledges that Ethicon has done no testing of any kind on the suitability of, and therefore has no data regarding the safety or efficacy of, using the Mesh
as a raw material or otherwise in the manufacture of DERMAGRAFT®. Advanced BioHealing represents and warrants that it will only use the Mesh for its own use as a raw material in the manufacture of DERMAGRAFT® that Advanced BioHealing
manufactures and it will not resell or otherwise use the Mesh. Advanced BioHealing represents and warrants that subject to Section 3(b) below, it will only promote and distribute DERMAGRAFT® for its approved uses. Advanced BioHealing
further represents and warrants that, subject to paragraph 3(b) below, it will only utilize the Mesh as a raw material to manufacture DERMAGRAFT® that (i) if manufactured for distribution in the United States, has received marketing
approval from the U.S. Food & Drug Administration and (ii) if manufactured for distribution in a territory other than the United States, has received marketing approval from the applicable agency in such territory. Advanced BioHealing
acknowledges and agrees that there shall be no returns of Mesh except for Mesh that is damaged or defective. 
 (b) Made by
Ethicon. Ethicon represents and warrants that the current material specification for the Mesh is attached hereto as Exhibit A (the “Specifications”) and that the Mesh is fabricated from [***]. If the Mesh provided by Ethicon to
Advanced BioHealing does not conform to the Specifications, Ethicon’s sole liability shall be to [***] Advanced BioHealing with replacement Mesh that does conform to the Specification at no additional charge. This shall be Advanced
BioHealing’s sole and exclusive remedy. Ethicon will notify Advanced BioHealing two (2) months in advance of any changes to be made to the composition, construction or properties of 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 the Mesh or any intention to discontinue the manufacture and supply of the Mesh. ETHICON MAKES NO
OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE MESH. 
 2. Release & Indemnity. In consideration of Ethicon agreeing to furnish the Mesh and to induce Ethicon to furnish such Mesh, Advanced BioHealing does hereby, for itself, its
successors and assigns, release and forever discharge Ethicon and the affiliates of Ethicon, including without limitation Johnson & Johnson, and the directors, officers and employees of such entities (collectively, the
“Releasees”) from any and all Claims arising from, based upon or relating to the design, manufacture, promotion, sale or use of DERMAGRAFT® incorporating or otherwise utilizing the Mesh. “Claims” means any and all claims
(whether known or unknown or suspected or unsuspected), demands, causes of action, actions, suits and proceedings, of every nature including, without limitation, claims for death or injury to person or damage to property (whether based on breach of
contract, breach of warranty, negligence, strict liability or other theory of liability). 
 In addition, Advanced BioHealing hereby agrees to
indemnify and hold harmless, Ethicon and the other Releasees from and against any and all liabilities and losses (including, without limitation, those arising out of any Claim, such as any settlement or compromise thereof or judgment or award
therein), damages (including, without limitation, incidental and consequential damages), costs and expenses (including, without limitation, attorney’s fees and expenses incurred in defending any Claim or asserting any rights hereunder) arising
from or in connection with (i) the assertion by Advanced BioHealing (or its successor or assign) of any Claim released pursuant to this Agreement or (ii) the assertion by a third-party of any Claim arising from, based upon or relating to
the design, manufacture, promotion, sale or use of DERMAGRAFT® incorporating or otherwise utilizing the Mesh. This release and indemnity shall survive the delivery and acceptance of the Mesh. 

3. Insurance. 

(a) Base Insurance for Permitted Uses. Advanced BioHealing shall, at its own expense, obtain and maintain until the expiration of
all DERMAGRAFT® containing the Mesh (i) product liability insurance providing protection in the amount of at least [***] Dollars ($[***]) per occurrence and annual aggregate against any Claims, liabilities, losses or damages
based upon any alleged defect in, or otherwise caused by, DERMAGRAFT® (ii) general liability insurance providing protection in the amount of at least [***] Dollars ($[***]) per occurrence and annual aggregate against any
Claims, liabilities, losses or damages based upon any act or alleged activity of Advanced BioHealing. In the event that such insurance is written on a claims made basis, such insurance shall have an retroactive date prior to the effective date of
this Agreement and Advanced BioHealing shall, on the later of (i) the [***] and (ii) the [***] of DERMAGRAFT®, at its own expense, obtain and maintain a tail policy for [***] thereafter. In the event Advanced
BioHealing cannot obtain product liability insurance on commercially reasonable terms, it may provide for the insurance described in clause (i) above through a program of self-

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
insurance with limits of not less than those specified in clause (i) above. Advanced BioHealing agrees to notify Ethicon of the institution of the self-insurance program and include with
such notice a description of the program. Each policy shall be endorsed to specifically name Ethicon as an additional insured and to provide that the policy cannot be changed, modified or canceled without at least thirty days’ prior written
notice to Ethicon. Advanced BioHealing shall furnish to Ethicon, upon request and at least annually, a certificate of insurance evidencing compliance with the provisions of this paragraph. The existence of this insurance coverage shall in no way
limit Advanced BioHealing’s liability or obligations hereunder. 
 (b) Expanded Insurance for Additional Uses.
Advanced BioHealing may, from time to time, manufacture DERMAGRAFT® containing Mesh for itself or third parties for clinical applications in addition to its current FDA approved indications, which, as of the date hereof are: 1) the treatment of
full thickness diabetic foot ulcers greater than six weeks duration which extend through the dermis but without tendon muscle, joint capsule or bone exposure; and 2) the treatment of wounds associated with Dystrophic Epidermolys Bullosa (EB). In
such case, and provided that the clinical use is approved by the applicable U.S. or foreign regulatory authority, Ethicon agrees that Advanced BioHealing may utilize the Mesh as a raw material to manufacture the DERMAGRAFT® provided that
Advanced BioHealing has previously provided written evidence to Ethicon that it has increased its products liability insurance that it is required to obtain and maintain pursuant to Section 3(a) to at least [***] Dollars ($[***])
per occurrence and annual aggregate. 
 4. Price. Ethicon agrees to sell the Mesh to Advanced BioHealing at [***].

 5. Forecast; Bulk Orders. 
 (a) Forecasts. At the beginning of each [***], Advanced BioHealing shall provide Ethicon with [***] forecast of Advanced BioHealing’s expected requirements for Mesh during the
following [***] (the “Forecast”) broken down by [***]. The first [***] of each such Forecast [***]. Advanced BioHealing will issue purchase orders to Ethicon with delivery dates no less than [***] after
the issuance of such purchase orders. 
 (b) Bulk Orders. Within [***] days of being notified that Ethicon intends
to 1) terminate this Agreement, 2) make changes to the Specifications or 3) discontinue the manufacture and supply of the Mesh, Advanced BioHealing shall have the right to place a one time, non-cancelable order, herein called Bulk Order, for up to a
maximum of [***] boxes of Mesh ([***] sheets per box). Ethicon has the right to fill the Bulk Order over a [***] period, with shipments of [***] of the order each [***] of the period or [***], and subject to
this limitation, Advanced BioHealing shall have the right to place partial orders for the Bulk Order within the described time-table. The parties may change the time-table for delivery of the Bulk Order by mutual agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 6. Supply Efforts and Allocation. Ethicon will use its commercially reasonable efforts to
fulfill orders for Mesh placed by Advanced BioHealing; however, Ethicon will not be liable for any delay in delivery or other delay or failure to supply the Mesh [***]. Subject to the prior sentence, in the event of a shortage of Mesh,
Ethicon may allocate product as it determines in its sole and absolute discretion. 
 7. Termination for Convenience. Either party
may terminate this Agreement for any reason upon at least two (2) months advanced notice. 
 8. Confidentiality; Publicity.
The terms and conditions of this Agreement and the Specifications shall be held in strict confidence by Advanced BioHealing. Advanced BioHealing shall not publicly announce or disclose this Agreement or its purchase of Mesh from Ethicon in
connection with this Agreement, without Ethicon’s prior written consent. Advanced BioHealing shall not use Ethicon’s name in any way, including without limitation as a supplier, without Ethicon’s prior written consent. Any violation
of this paragraph shall entitle Ethicon, in addition to seeking any other available remedies, to immediately, and without liability, terminate any and all outstanding purchase orders for Mesh. 

9. Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey
without regard to any choice-of-law rules. 
 10. Dispute Resolution. Any controversy or claim arising out of or relating to this
Agreement shall be resolved by arbitration before a single arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) then pertaining (available at www.adr.org), except where those rules
conflict with this provision, in which case this provision controls. Any court with jurisdiction shall enforce this clause and enter judgment on any award. The arbitrator shall be selected within twenty business days from commencement of the
arbitration from the AAA’s National Roster of Arbitrators pursuant to agreement or through selection procedures administered by the AAA. Within [***] days of initiation of arbitration, the parties shall reach agreement upon and
thereafter follow procedures, including limits on discovery, assuring that the arbitration will be concluded and the award rendered within no more than [***] from selection of the arbitrator or, failing agreement, procedures meeting such time
limits will be designed by the AAA and adhered to by the parties. The arbitration shall be held in New Jersey and the arbitrator shall apply the substantive law of New Jersey, except that the interpretation and enforcement of this arbitration
provision shall be governed by the Federal Arbitration Act. Prior to appointment of the arbitrator or thereafter if he is unavailable, emergency relief is available from any court to avoid irreparable harm. THE ARBITRATOR SHALL NOT AWARD EITHER
PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, OR ATTORNEYS FEES OR COSTS; PROVIDED, THAT, THE FOREGOING LIMITATIONS OF LIABILITY WILL IN NO EVENT LIMIT THE INDEMNIFICATION RIGHTS AND OBLIGATIONS OF A PARTY UNDER PARAGRAPH 2 ABOVE.

 Prior to commencement of arbitration, the parties must attempt to mediate their dispute using a professional mediator from AAA, the CPR
Institute for Dispute Resolution, or like organization 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
selected by agreement or, absent agreement, through selection procedures administered by the AAA. Within a period of [***] days after the request for mediation, the parties agree to
convene with the mediator, with business representatives present, for at least one session to attempt to resolve the matter. In no event will mediation delay commencement of the arbitration for more than [***] days absent agreement of the
parties or interfere with the availability of emergency relief. 
 11. Notices. Any notice under this Agreement shall be mailed to
the recipient at its address set forth above or at the address subsequently designated by a party as the address for receipt of notices. 
 12.
Entire Agreement. To the extent of any conflict or inconsistency between this Agreement and the terms and conditions of any purchase order, purchase order Agreement, confirmation, acceptance, invoice, or any similar document or
instrument relating to the purchase of the Mesh (each a, “Related Sale Document”), the terms of this Agreement shall govern. This Agreement together with the Related Sale Documents shall govern the purchase of the Mesh and constitute the
entire agreement of the parties, and supersede all previous negotiations or agreements, either oral or written, between the parties with respect to the subject matter of this Agreement. 
 13. Amendment; Waiver. This Agreement may be amended, modified or supplemented and a term hereof waived, in each case, only by a written instrument executed by both parties hereto.

 14. Binding Effect; Assignment. This Agreement shall inure to the benefit of, and be binding upon, Advanced BioHealing and
Ethicon and the other Releasees, and their respective successors, assigns, heirs, executors and administrators; however, this Agreement shall not be assigned, in whole or part, by Advanced BioHealing without the prior written consent of Ethicon,
which consent may be given or denied at Ethicon’s sole discretion. Any assignment in violation of this paragraph shall be null and void. 

15. Severability. The invalidity or unenforceability of any provision of this Agreement shall in no way affect the validity or
enforceability of any other provision of this Agreement. 
 16. Enforceability. Advanced BioHealing irrevocably covenants that it
will not assert any Claim based, in whole or part, on any matter released hereby or on the grounds that any or all of the terms or provisions of this Agreement are illegal, invalid, not binding, unenforceable or against public policy. 

[The remainder of this page is intentionally blank] 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 If you are in agreement with the terms set forth above and desire to proceed on such basis, please sign in
the space provided below and return an executed copy of this letter agreement to Dr. Richard Gooding, by faxing it to (908) 218-2594 and by mailing it to ETHICON, Inc., Attn: Richard Gooding, P.O. Box 151, Route 22 West, Somerville, NJ
08876-0151. 
  

			
	ETHICON PRODUCTS DIVISION
	ETHICON, INC.
		
	By:	 	/s/ Gary Pruden
	Gary Pruden
	Worldwide President, Ethicon Products Division

Agreed to as of the date first above written: 
  

			
	ADVANCED BIOHEALING, INC.
		
	By:	 	/s/ Gerald F. Vovis
	Title: Gerald F. Vovis
	VP & General Manager

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

  
 Exhibit A 
  
 MATERIAL SPECIFICATION FOR 

UNDYED KNITTED VICRYL* (POLYGLACTIN 910) MESH (STYLE [***]) 
 Revision History for (MS732-001) 
  

							
	 Revision #
 (Insert the
Rev # in
ascending
order)
	  	 Summary of Change

(Describe the change, and the section of the
 document where the change occurred.)
	  	 Change Order #

(Insert the
associated
change order#)
	  	 Originator

(Insert the
author of the
document or
change)

	28	  	Removed form as attachment in MS732-001. Referenced new form for recording [***]FM-0000777. Revised form to remove [***]Removed information contained on Data Summary
sheet.	  	CO-0013886	  	P. Tilson
				
	27	  	Revised to change the reference document for [***]TM403-091 to TM403-576.	  	CO-0011443	  	P. Tilson

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

  
  

	1.	Purpose 

  

	 	1.1	To provide the requirements and test procedures for VICRYL* (polyglactin 910) mesh, knitted Style [***] and the finished product. 

NOTE:            [***] 

 

	2.	Scope 

  

	 	2.1	Describes the construction identity and physical test on undyed knitted VICRYL* (polyglactin 910) mesh, Style [***], [***] [***] ETHICON, INC., Cornelia, Georgia, [***]

  

	 	2.2	Describes the appearance, chemical and physical testing, and packaging requirements for processed undyed knitted VICRYL Mesh after [***] 

 

	3.	References  

 [***]

 [***] 

[***]        [***] 

 

	4.	Construction 

  

	 	4.1	This mesh is fabricated from [***] 

  

	5.	Records 

  

	 	5.1	ETHICON, Cornelia will utilize its lot numbering system and maintain records which will permit identification of all [***] 

 

	6.	Requirements for Undyed Knitted VICRYL Mesh, Style [***] (see appendix II for documentation) 

 

					
	 Characteristic
	  	 Requirements
	  	 Test Method

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

  
  

	7.	Packaging ([***] ETHICON, Cornelia). 

 NOTE:     [***] 
 [***] 

[***] 
 [***]

 [***] 
  

	8.	Quality Requirements 

  

	 	8.1	Requirements for Undyed Knitted VICRYL Mesh after [***] 

  

	
	[***]

  

	
	[***]
	
	[***]

  

	
	[***]

  

	
	[***]

  

	9.	Requirements for Undyed Vicryl Mesh after [***] 

  

	
	 [***]
  
 [***].

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

  
  

	10.	Packaging Requirements 

  

	 	10.1	[***] 

  

	11.	Package Integrity 

 [***]

  

	12.	Shipping 

 [***]

  

	13.	Appendices 

  

	 	13.1	APPENDIX I, Vicryl* Mesh Style [***] 

  

	 	13.2	APPENDIX II, Test Form for Received Mesh 

  

	 	13.3	APPENDIX III, Test Record for Finished Mesh 

/ / 

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

 QA PAGE 1 OF 3 

 
  

	1.	Special Instructions 

[***]        [***]        1.2 Sampling Plan 

[***] 
  

	 	1.3	Records 

  

	 	1.3.1	Record data on appropriate worksheet. 

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

 QA PAGE 2 OF 3 

 
 [***] 

 

	 	1.3	Release material according to [***]. 

  

	2.	Testing Criteria (see appendices II, III, and IV for documentation) 

  

													
	 Characteristic
	  	 Class
	 	  	 Sample Size/Frequency
	 	  	 Accept/Reject
	 
	 [***]
	  				  				  			

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

 QA PAGE 3 OF 3 

 
  

	3.	APPROVED SUPPLIERS 

  

							
	3.1	 	Supplier	 	Applies to RMC #	 	
				
		 	[***]	 	Supplier Certificate: Not applicable.	 	

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	MS732-001
	  	Revision:	  	28

  
 APPENDIX I 
 VICRYL MESH STYLE [***] 

[***] 
 NOTE:
This diagram has been increased in size. 

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	[***]
	  	Revision:	  	28

  
 Appendix II 
 VICRYL MESH – AS RECEIVED 

 

													
	[***] JOB LOT NUMBER	 	  
	 	[***] LOT NUMBER	 	  
	 		 	

													
							
	TEST DATE	 	  
	 		 		 		 	TESTED BY	 	  

											
						
	STYLE	 	  
	 	ROLL NUMBER	 	  
	 	ITEM NUMBER	 	  

 

									
	CONSTRUCTION:	 	Pass             	  	Fail             	  		  	

  

	
	 REQUIREMENT:
                                        

 [***]

  

	
	[***]

  

									
	VERIFIED BY:	 	  
	 		 	DATE:	 	  

 

					
	FINAL DISPOSITION
			
	ACCEPT  ̈       REJECT  ̈	  	INITIALS:                     	 	DATE:
                    

							
		
	COMMENTS:	 	  

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	

	  	Document Name (#):	  	[***]
	  	Revision:	  	28

  
 Appendix III 
 VICRYL MESH – FINISHED 

 

													
	JOB LOT / [***] NUMBER	 	  
	 		 	[***] NUMBER	 	  
	 	

													
							
	TEST DATE	 	  
	 		 		 	ROLL NUMBER	 	  
	 	

											
						
	STYLE	 	  
	 	EXT. LOT	 	  
	 		 	

 [***] 

TESTED BY:
                                         
                
 [***] 

TESTED BY:
                                         
                
  

	
	[***] TESTED
BY                                        
                                    DATE    
                                        

  

															
	VERIFIED BY:	 	  
	 		 	DATE:	 	  
	 		 		 	

  

					
	FINAL DISPOSITION
			
	ACCEPT  ̈       REJECT  ̈	  	INITIALS:                     	 	DATE:
                    

			
		
	COMMENTS:	 	  

  
 *** Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Supply Agreement

 Exhibit 10.29 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 SUPPLY AGREEMENT 
 THIS AGREEMENT (the “Agreement”), entered into as of this 10th day of January, 2007 (the “Effective Date”), by and between HyClone Laboratories, a corporation organized under the laws
of Utah with a place of business at 925 West 1800 South, Logan, UT 84321 (“Supplier”), and Advanced BioHealing, Inc., a Delaware Corporation with a place of business at 10933 North Torrey Pines Road, Suite 200, La Jolla, California 92037
(“ABH”). 
 W I T N E S S E T H: 
 WHEREAS, Supplier has experience in the production of the materials described in Exhibit A hereto (the “Materials”), some or all of which are based on custom specifications supplied by ABH and
which include both standard and custom sera, media and bioprocess containers; and 
 WHEREAS, ABH desires to purchase Materials
from Supplier for use by ABH in certain of its products and Supplier desires to manufacture and supply the Materials to ABH in accordance with the specifications set forth in Exhibit A (the “Specifications”) hereto, which is expressly
incorporated by reference, and the terms and conditions set forth herein; and 
 WHEREAS, Supplier is willing to sell to ABH,
and ABH is willing to purchase the Materials from Supplier in accordance with the price and other terms set forth herein, 

NOW, THEREFORE, the parties hereto agree as follows: 
 ARTICLE I 
 MANUFACTURE AND SALE 

1.01 Supply. During the term of this Agreement and subject to the terms and conditions set forth herein, Supplier shall manufacture and
supply to ABH (or a designated affiliate of ABH), and ABH shall purchase from Supplier, the Materials in such quantities as from time to time may be ordered by ABH as provided herein. If ABH defaults under this Agreement, then Supplier may refuse to
deliver Materials to ABH without being liable for breach (or in its sole discretion Supplier may condition any delivery upon cash payment). Any Materials added to the Agreement after the date hereof (with attendant prices and Specifications) must be
approved in writing by both parties, and any custom Materials must comply with Supplier’s standard contract review process. All Materials shall be supplied with a minimum of at least [***] of the time remaining on their expiration date.

 1.02 Quality of Materials. Supplier agrees to adhere faithfully to the Specifications processes and all applicable regulatory
requirements relating to the manufacture of the Materials and shall not deviate in any way whatsoever therefrom without the prior written consent of a duly authorized representative of ABH. 

1.03 Custom Materials. ABH represents and warrants to Supplier that: (a) ABH has acquired from Smith & Nephew Wound
Management (La Jolla) (“SNWM”) certain assets 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
related to the Specifications and intellectual property rights for all custom Materials (collectively the “Custom IP”) that were previously held by SNWM and that were covered by a
Supply Agreement dated 19 May 2005 between Supplier and SNWM and (b) ABH has the legal right to disclose the Custom IP to Supplier for the purpose of manufacturing Materials for ABH under this Agreement, subject to the confidentiality
provisions of this Agreement. SNWM has confirmed in writing to Supplier that SNWM has no objection to Supplier and ABH entering into this Agreement for the supply of the same custom Materials to ABH that Supplier previously manufactured for SNWM.

 ARTICLE II 
 PRICE, ORDERS, AND TERMS OF PAYMENT 
 2.01 Price. ABH shall pay Supplier the
prices for the Materials as shown in Exhibit B hereto, which is expressly incorporated by reference, less applicable allowances. These prices shall be firm and not subject to change through 31 December 2007. Prices during each new calendar year
after 2007 will be adjusted by mutual written agreement of the parties, as evidenced by the parties’ signing a replacement Exhibit B for that calendar year. Supplier will propose to ABH, and the parties will negotiate in good faith, these new
prices at least sixty (60) days before the start of each calendar year for an effective date beginning in January of the new calendar year; however, the new prices shall not exceed by more than [***] the previous year’s prices
unless due to increases in raw material costs or other extenuating circumstances. If the parties cannot agree upon pricing for a new calendar year, then either party may refer the pricing decision to an independent third party for resolution by
binding arbitration by giving the other party written notice after the sixty (60) day period referred to above has expired. The third party arbitrator must be approved by both parties, and the arbitrator shall be charged with determining the
fair market pricing for the Materials for the new calendar year, considering, among other things, Supplier’s direct costs, a reasonable profit margin for Supplier–for this purpose Supplier’s historic profit margins on the Materials
shall be relevant–and other commercially reasonable factors. The prices are F.O.B. place of [***]. Supplier reserves the right to renegotiate and adjust pricing if there are changes in Specifications, manufacturing processes or
documentation that are requested by ABH and agreed to by Supplier, and until the new pricing is agreed upon, Supplier may continue to manufacture the Materials pursuant to this Agreement. Pricing includes Supplier’s standard packaging, labels
and raw material and production costs; it does not include the following, which ABH shall pay (Supplier may prepay the following charges and add them to the invoice price for reimbursement by ABH): federal, state and local sales, use, excise and
other taxes; customs duties; freight; special packaging; dry ice; and any insurance desired by ABH. 
 2.02 [DELIBERATELY LEFT
BLANK] 
 2.03 Purchase Orders. ABH shall submit purchase orders for the Materials to Supplier at its address designated in
Section 8.06 hereof. Such purchase orders shall set forth the quantities of Materials to be purchased, the delivery dates and shipping instructions, and shall allow at least ten (10) weeks for orders, except that a standing order will ship
eight (8) weeks from the date that ABH requests samples, unless otherwise agreed to by both parties in writing. Supplier will make commercially reasonable efforts to meet delivery dates and expects to do so,

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
however, in the event of any foreseeable delay Supplier shall promptly inform ABH of such delay. Supplier shall have no legal liability to ABH for failure to complete or deliver a purchase order
by the delivery date indicated, unless the delay is within Supplier’s reasonable control or if Supplier does not promptly notify ABH in writing of a delay. Each purchase order issued hereunder shall be governed by the terms of this Agreement,
and none of the terms or conditions of ABH’s or Supplier’s forms shall be applicable, except those specifying quantity ordered, delivery dates, special supply and packing instructions, and invoice information. 

2.04 Payment Terms. Net payment for the Materials shall be due to Supplier not later than thirty (30) days from the date of
Supplier’s invoice for Materials. ABH shall pay Supplier interest at the rate of [***] per annum on any past due payments. All payments and communications regarding the Materials shall be delivered to Supplier at the address designated
in Section 8.06 hereof. 
 2.05 Availability. Supplier’s obligations under this section are subject to the allocation
provisions of Section 2.08 hereof and the force majeure provisions of Section 8.01 hereof. Supplier agrees to provide the Materials to ABH during the term of the Agreement. Supplier shall give at least twelve (12) months written
notice (for standard sera and standard media Materials), and six (6) months written notice (for custom sera and custom media Materials and for bags and bioprocess containers) to ABH in the event Supplier elects to withdraw from the business of
manufacturing any given Material. In such event (and notwithstanding any contrary provisions in Section 2.06), ABH reserves the option to buy up to [***], for sera and media, and up to [***], for bags and bioprocess containers, of
the then annual forecasted level of Material before the discontinuation date (any delays in delivery past the discontinuation date, other than deliveries made under the standard provisions of Section 2.03, must be mutually agreed to by the
parties in writing at the time ABH places a purchase order). After the discontinuation date, this Agreement shall terminate as to the discontinued Material. 
 2.06 Forecasts. On the Effective Date and on or before the first day of each calendar quarter thereafter during the term of this Agreement, ABH will provide Supplier with written notice of ABH’s
estimate of the total quantity of Materials to be purchased by ABH for that quarter and the succeeding three quarters. The forecasts shall include estimates of desired delivery dates and the amount of Materials to be delivered on the delivery dates.
Forecasts submitted by ABH will be for general planning purposes and for Supplier’s purchase of raw material supplies and blending of custom Materials (i.e., Materials manufactured by Supplier to ABH’s custom specifications and not
included in Supplier’s general catalogues) for ABH in order to meet the forecast. Supplier must give its prior written approval: (a) for changes of more than [***] in the amount of Materials forecasted for delivery in a calendar
quarter in comparison to the prior forecast for that quarter (either up or down); and (b) if the amount of Materials actually ordered for a calendar quarter exceeds the forecast for that calendar quarter by more than [***]. Upon the
termination of this Agreement for any reason, ABH will purchase custom Materials that are then held by Supplier in inventory for which purchase orders or forecasts have been provided by ABH. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 2.07 Reservations. Subject to the limitations of this section and Sections 2.08 and 8.01
hereof, ABH has the right to reserve off-the-shelf (i.e., standard, catalogue) media or sera Material (the “Reserved Material”) and take shipments from the Reserved Material as needed. The quantity of Reserved Material at any given time
may not exceed [***] of the projected order quantity of that Material within the then current forecast described in Section 2.06 hereof. A reservation must comprise all or part of a single manufacturing lot (approximately two thousand
(2,000) units for media Reserved Material). To reserve Reserved Material, ABH shall issue a purchase order for the entire amount of the reserve. Should ABH determine that it does not require all or part of the Reserved Material, then ABH shall
advise Supplier as soon as possible in writing, and the Reserved Material shall be released from the reservation. If ABH does not take shipment of any Reserved Material within [***] after the reservation, then the Reserved Material shall be
released from the reservation upon Supplier’s giving ABH written notice thereof and ABH’s failing to take shipment of the Reserved Material within thirty (30) days after the notice. ABH agrees that it will not release back to Supplier
any Reserved Material once it has reached [***] expiry or less; instead, ABH shall take shipment of that Reserved Material. Supplier will provide prior updates and written notice of the expiration dating of Reserved Material. This section
does not apply to any custom media Material, custom sera Material or bioprocess container Material. 
 2.08 Allocation. If
Supplier has an insufficient supply of any Material to meet orders from all of its customers for that Material in a timely fashion, then Supplier shall allocate the available Material to ABH and Supplier’s other customers in a fair and
equitable manner, in accordance with Supplier’s reasonable allocation policies in effect on the date of allocation as disclosed to ABH. The parties agree that a “fair and equitable manner” includes an allocation based on [***].
However, during the first year of this Agreement, Supplier shall use the written estimate of the total quantity of Materials to be purchased by ABH that ABH shall provide to Supplier on the Effective Date as stipulated in Section 2.06.

 ARTICLE III 
 DELIVERY AND TITLE 
 3.01 Terms of Delivery. The Materials shall be shipped F.O.B.
[***] with freight charges prepaid and added to invoice, unless otherwise instructed by ABH and approved by Supplier, each in writing. Supplier will ship Materials at the specified temperatures, if any, that are set forth in the
Specifications for those Materials that are attached hereto as Exhibit A. Supplier will use a validated shipping method and supply documentation to support that the Material is shipped at the specified temperature. If Material is not shipped at
specified storage temperature, replacement Material will be sent at no charge to ABH, and Supplier will pay the freight charges. 
 3.02 Manufacture of Materials. 
 (a) The Materials shall be manufactured in
accordance with all applicable regulatory standards, including without limitation the ISO 9000 series of standards. Supplier shall promptly advise ABH in writing of any proposed raw material, or Specification changes, or

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
any significant process change by Supplier in the manufacture of Materials, which changes must be approved by ABH in writing prior to their implementation by Supplier but which approval shall not
be withheld unreasonably. In the event ABH and Supplier are unable to agree on such changes, Supplier shall assist ABH in good faith to secure an alternate manufacturer of the Materials, but subject to the provisions of Section 2.08 hereof on
allocation and Section 8.01 hereof on force majeure (including the availability of raw material sources) Supplier shall continue to supply Materials to ABH pursuant to the original Specifications until (i) such alternate manufacturer is in
a position to supply Materials to ABH, or (ii) for a period of [***] for standard media Materials and standard sera Materials and [***] for custom media Materials, for custom sera Materials and for bioprocess container Materials,
whichever of (i) or (ii) is less. ABH (or a third party designated by ABH and reasonably acceptable to Supplier) shall have the right to audit Supplier for compliance with applicable regulatory requirements at reasonable intervals. Such
audits shall be scheduled at mutually agreeable times (subject to Supplier’s audit scheduling procedures, but in no event sooner than fifteen (15) days after ABH’s request) and shall be subject to the confidentiality provisions of
article V. 
 (b) Each party shall promptly advise the other in writing of any safety or toxicity problems of which either party
becomes aware regarding the Materials or intermediates used in the manufacture of the Materials. 
 (c) Supplier shall promptly
notify ABH in writing (no later than within seven (7) days) of any regulatory actions filed against Supplier by the FDA or its foreign regulatory equivalent/counterpart that adversely affects the manufacture of the Materials. 

3.03 Inspection. Within a reasonable time (but no later than sixty (60) days) after arrival of the Materials at ABH’s
manufacturing facility, ABH may inspect and test the Materials at its own cost. If ABH finds that the Materials do not conform to the Specifications, then ABH shall promptly (but in no event later than sixty (60) days after the date of such
arrival), give Supplier written notice of any claim setting forth the details of such non-conformity. If Supplier does not acquiesce to such notice, then acceptability or rejection will be determined by the outcome of testing by a third party
acceptable to and agreed upon in writing by both Supplier and ABH. Any costs for the third party testing will be borne by the non-prevailing party. If any Materials are non-conforming, then as ABH’s sole remedy (other than the indemnity
provisions of Section 4.03 hereof) Supplier shall promptly refund the purchase price for such nonconforming Material or replace, at its expense, any non-conforming Materials with fully conforming replacement Material within six (6) weeks
after Supplier receives the above mentioned written notice from ABH. Replacement costs paid for by Supplier shall include packaging, freight costs and/or disposal of nonusable Materials as well as the replacement cost of the non-conforming Material
itself. 
 3.04 Performance. If Supplier does not make timely deliveries of Materials to ABH at least [***] of the time
(here “timely” means no more than [***] late and no more than [***] early in relation to a requested delivery date), then at ABH’s request Supplier may be required to complete a “Supplier Corrective Action
Request” form and return same to ABH within thirty (30) days of receipt; provided, however, that Supplier’s liability for failing to meet delivery dates is limited as described in Section 2.03. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 3.05 Subcontractors. The terms of this Agreement apply to all services and parts that
Supplier shall provide to ABH including but not limited to services and parts acquired from other sources to meet the Specifications. 
 3.06 Authorized Release. Supplier’s regulatory affairs / compliance officer for the Materials shall be responsible for release of the Materials. 

ARTICLE IV 

WARRANTIES, INDEMNITIES AND INSURANCE 
 4.01 Warranties. Supplier warrants to ABH that Materials delivered to ABH pursuant to this Agreement shall conform with the Specifications and that such Materials shall (i) be free from defects in
material and workmanship, (ii) be in compliance with applicable law and all regulatory requirements and (iii) be manufactured in accordance with this Agreement and (iv) not be adulterated within the meaning of applicable federal law
and compliant with current good manufacturing practices under 21 CFR part 810, if applicable. Supplier further warrants that to the best of Supplier’s knowledge the Materials do not infringe any United States or foreign patent or any other
intellectual property right, but this infringement warranty shall not be applicable to the extent that any Specifications are supplied to Supplier by ABH. SUPPLIER MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE MATERIALS. ALL
OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY SUPPLIER. ABH’S SOLE REMEDY FOR A BREACH OF THESE WARRANTIES (OTHER THAN
THE INDEMNITY PROVISIONS OF SECTION 4.03 HEREOF) IS REFUND OR REPLACEMENT, as described in Section 3.03 hereof. Supplier shall not be responsible for any defects created in a Material after the Material has been received, inspected and accepted
by ABH; however, subject to limitations that are set forth elsewhere in this Agreement, Supplier shall be responsible for latent defects in the Materials, but claims for such latent defects must be raised, if at all, within twelve (12) months
after the Materials have been shipped to ABH. ABH warrants to Supplier that to the best of ABH’s knowledge any custom formulation or Specifications provided to Supplier do not infringe any United States or foreign patent. Changes to
Specifications will not be implemented until ABH has approved the revised Specifications in accordance with Section 3.02(a) hereof. 
 4.02 Specifications. ABH shall deliver to Supplier written notice of any required changes to the Specifications of any custom Materials, and Supplier will advise ABH in writing within twenty
(20) days after receiving the notice whether Supplier is willing to accommodate such changes in Specifications, and the parties shall mutually agree upon any corresponding price adjustment, which shall be implemented by following the procedures
set forth in Section 2.01 hereof. 
 4.03 Indemnities. ABH shall indemnify and hold harmless Supplier from and against any
and all claims, demands, actions, suits, causes of action, damages and expenses (including but not limited to expenses of investigation, settlement litigation and reasonable attorneys’ fees

 
incurred in connection therewith) which are hereafter made, sustained or brought against Supplier by any person for the recovery of damages for property damage or bodily injury, illness or death
of any person caused or alleged to be caused by Specifications supplied to Supplier by ABH (including, without limitation, any infringement of intellectual property rights of a third party) or by the use of any ABH materials that include the
Materials, except to the extent that such claims, demands, actions, suits, causes of action, damages or expenses occur as a result of Supplier’s negligence, willful misconduct, breach of this Agreement or breach of its warranties contained in
Section 4.01 hereof. In turn, Supplier will indemnify and hold harmless ABH from and against any and all claims, demands, actions, suits, courses of action damages and expenses (including but not limited to expenses of investigation, settlement
litigation and reasonable attorneys’ fees incurred in connection therewith) which are hereafter made, sustained or brought against ABH by any person for the recovery of damages for property damage or bodily injury, illness or death of any
person arising out of or resulting from Supplier’s negligence, willful misconduct, breach of this Agreement or breach of the warranties set forth in Section 4.01 hereof (including, without limitation, Supplier’s warranties in such
section relating to any infringement of intellectual property rights of a third party), except to the extent that such claims, demands, actions, suits, causes of action, damages or expenses occur as a result of ABH’s negligence or willful
misconduct. As to any intellectual property infringement claims under this Agreement, the indemnifying party shall have the right to take anyone or more of the following actions (a) to procure a license from the person claiming or likely to
claim the infringement, (b) to modify the Materials to avoid the claim of infringement, so long as the modification does not materially impair the quality of the Materials, (c) if Supplier is the indemnifying party, then to accept the
return of the Materials subject to or likely to be subject to the claim and to refund to ABH the price paid for the Materials (including shipping charges), and/or (d) to assume the defense of the claim at the indemnifying party’s cost
(with the indemnified party agreeing to cooperate with the indemnifying party in the defense). 
 4.04 Insurance. Each party
warrants to the other that it is currently insured and covenants that at all times during the term of this Agreement it will maintain a commercial general liability insurance policy which is sufficient to protect against the risks associated with
its ongoing business, including the risks which might possibly arise in connection with the transactions contemplated by this Agreement, with limits of at least of [***] per occurrence and [***] in the aggregate. Each party shall
continue to maintain such insurance during the term of this Agreement and thereafter, until a commercially reasonable time after ABH has ceased to market any products which incorporate the Materials. 

4.05 Limitation of Liability. EXCEPT FOR ANY CLAIMS HEREUNDER BASED ON INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHT, AND THE INDEMNITY
AND CONFIDENTIALITY PROVISIONS HEREOF, NEITHER PARTY SHALL BE LIABLE FOR, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS, ANY LIABILITY FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, OR CONSEQUENTIAL DAMAGES TO THE OTHER PARTY RESULTING FROM, CAUSED BY,
RELATING TO, OR ARISING OUT OF THE USE OF THE MATERIALS, A BREACH OF THIS AGREEMENT, THE BREACH OF ANY REPRESENTATION OR WARRANTY, OR ANY OTHER THEORY, WHETHER SOUNDING IN TORT OR IN CONTRACT. HOWEVER,

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
NOTHING IN THIS AGREEMENT WILL LIMIT A PARTY’S LIABILITY FOR FRAUD OR FOR DEATH OR PERSONAL INJURY CAUSED BY A PARTY’S NEGLIGENCE OR WILLFUL MISCONDUCT. 

ARTICLE V 

CONFIDENTIALITY 

5.01 Confidential Information. All confidential information furnished by ABH to Supplier or any of its affiliates, or by Supplier to ABH
or any of its affiliates, during the term of this Agreement, relating to the subject matter hereof (“Confidential Information”) shall be kept confidential by the party receiving it for ten (10) years after the termination of this
Agreement, and the party receiving Confidential Information shall not make use of it except for purposes authorized by this Agreement, nor disclose any Confidential Information to any person or firm unless previously authorized in writing to do so;
provided, however, that the party receiving Confidential Information may disclose it as necessary to responsible officers, employees and independent contractors for the purpose contemplated by this Agreement, provided that such officers, employees
and independent contractors shall have assumed like obligations of confidentiality. 
 5.02 Other Information. The foregoing
limitations on the use and disclosure of Confidential Information shall not apply to information which: 
 (a) is required to be
disclosed by any applicable law, government regulations, or a court of competent jurisdiction provided the recipient has given the disclosing party prior written notice and provides reasonable assistance so as to afford the disclosing party the
opportunity to object and to protect from disclosure the maximum amount of such Confidential Information. 
 (b) at the time of
disclosure or thereafter lawfully becomes a part of the public domain; 
 (c) was otherwise in the receiving party’s lawful
possession prior to disclosure as shown by its written records; 
 (d) is released from confidential status by mutual written
agreement of the parties; or 
 (e) has been independently developed by the receiving party and such development can be proved
by clear and convincing documentary evidence. 
 5.03 Publicity. Except as may be required by applicable laws and regulations or
a court of competent jurisdiction, as required to meet credit or other financing arrangements, or as required or appropriate in the reasonable judgment of either party to satisfy the disclosure requirements of any applicable securities law or
regulations, neither party shall make any public release or other disclosure with respect to this Agreement or the terms hereof without the prior written consent of the other party. 

 ARTICLE VI 
 RIGHTS TO MATERIALS 
 6.01 Ownership. Supplier shall be the owner of all right,
title and interest in and to the standard off the shelf Materials prior to shipment to ABH, as well as any patent rights which may be obtained thereon. ABH shall be the owner of all right, title and interest in and to the custom Materials developed
with confidential information provided to Supplier by ABH; provided, however, that: (a) Supplier shall retain the right to any base formulations that are modified with confidential information supplied by ABH; and (b) Supplier may
manufacture and sell to other customers derivations and improvements to Supplier’s formulations that are based wholly on or developed wholly in response to information provided to Supplier by another customer without reference to intellectual
property, information or improvements provided by ABH. ABH shall be the owner of all right, title and interest in and to any inventions and confidential information supplied to Supplier by ABH forming part of the Specifications, as well as any
patent rights or other intellectual property rights which may be obtained thereon. Supplier may not use the Specifications for custom Material incorporating confidential information of ABH for any purpose other than the supply of Materials for ABH
hereunder. 
 ARTICLE VII 
 TERM AND TERMINATION 
 7.01 Term. Unless terminated in accordance with the
provisions of Section 7.02 below, this Agreement shall have an initial term of two (2) years, comprised of an initial twelve (12) month firm period and a second twelve (12) month cancellation period, which initial term shall
commence on the Effective Date of this Agreement. Upon each anniversary of the Effective Date of this Agreement, the term of the Agreement shall be automatically extended for an additional term of twelve (12) months, so that the term of this
Agreement on each anniversary date of the Effective Date shall recommence a new term of two (2) years made up of a twelve (12) month firm period and twelve (12) month cancellation period per section 2.05. Notwithstanding the
foregoing, at any time before the anniversary of an Effective Date, a party may give the other party written notice of cancellation of this Agreement, in which event this Agreement shall terminate at the end of then-scheduled cancellation period
rather than automatically extending for an additional twelve (12) month term on the next Effective Date as described above. 
 7.02 Early Termination. In addition to terminations made under Section 2.05, this Agreement may be terminated by either party as follows: 

(a) By either party immediately upon written notice by one party to the other, if the other party files or has filed against it a
petition under the Bankruptcy Act, makes an assignment for the benefit of creditors, has a receiver appointed for it or any of its assets; or 
 (b) By either party if the other party fails to perform or otherwise breaches any of its material obligations hereunder, by giving written notice of its intent to terminate and stating the grounds
therefor. The party receiving such notice shall have sixty (60) days from the receipt thereof if such breach or failure involves a non-monetary obligation, and thirty (30) days 

 
if the breach or failure is regarding a monetary obligation, to cure the failure or breach, at which time this Agreement shall terminate if such failure or breach has not been cured. In no event,
however, shall such notice of intention to terminate be deemed to waive any rights to damages or any other remedy which the party giving notice of breach may have as a consequence of such failure or breach. 

7.03 Effect of Termination. Termination of this Agreement, for whatever reason, shall not affect the obligations of either party as
specified in Sections 3.03, 4.01, 4.03 or 4.04, Articles V or VI hereunder. 
 ARTICLE VII 

GENERAL PROVISIONS 
 8.01 Force Majeure. Any delay or failure in the performance of any of the duties or obligations of either party hereto (except the payment of money) caused by an event outside the affected party’s
reasonable control and without the fault or negligence of the party so affected shall not be considered a breach of this Agreement, and the time required for performance shall be extended for a period equal to the period of such delay. Such events
shall include without limitation any delay for FDA approvals outside the affected party’s control; acts of God; acts of the public enemy; insurrections, civil disturbance, riots or armed conflict whether declared or undeclared; injunctions;
strikes, lockouts, concerted acts of workmen or other industrial disturbances; embargoes; fires, explosions, floods or other natural catastrophes; curtailment, shortage, discontinuation, rationing or allocation of normal sources of labor, materials,
transportation, energy or utilities and inability reasonably to obtain the same from others; sufferance of or voluntary compliance with acts of government and government regulation (whether or not valid); or other unforeseeable causes beyond the
reasonable control. The party so affected shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps are appropriate in that party’s discretion to relieve the effect of such cause as rapidly as possible.
Supplier’s obligations under this Agreement are at all times subject to the condition that Supplier is able to obtain a sufficient supply of raw materials on reasonable terms to manufacture Materials to sell to ABH. 

8.02 Assignment. Neither party shall assign this Agreement or any part thereof without the prior written consent of the other party,
which shall not be unreasonably withheld; provided, however, either party, without such consent, may assign or sell the same in connection with the transfer or sale of substantially its entire business to which this Agreement pertains, in the event
of its merger or consolidation with another company or in the event of the transfer or sale to a wholly-owned subsidiary or to an affiliated company. 
 8.03 Successors In Interest. Subject to Section 8.02, this Agreement shall be binding upon and inure to the benefit of the parties hereto, their subsidiaries, affiliates, successors and permitted
assigns. Assignment to an affiliate or subsidiary shall not release the party making such assignment from responsibility for its obligations under this Agreement. 
 8.04 Entire Agreement. This Agreement shall constitute the entire agreement between the parties hereto and shall supersede any other agreements, whether oral or written, express or

 
implied, as they pertain to the Materials. This Agreement may not be changed or modified except by written instrument signed by both parties. 

8.05 Relationship. The relationship created by this Agreement shall be strictly that of buyer and seller. Neither party is hereby
constituted an agent or legal representative of the other party for any purpose whatsoever, and is granted no right or authority hereunder to assume or create any obligation, express or implied, or to make any representation, warranties or
guarantees, except as are expressly granted or made in this Agreement. 
 8.06 Notice. Any notice required hereunder may be
served by either party on the other by personal delivery, by sending same, post-prepaid, by registered or by certified mail or by sending same guaranteed overnight express courier or delivery service, such as Federal Express, which provides for
evidence of receipt at the office of the intended addressee, each to the respective party’s address set forth below: 
  

			
	 ABH:
	  	 Advanced BioHealing, Inc.

10933 North Torrey Pines Road, Suite 200
 La
Jolla, CA 92037
 Attention: Gerald Vovis, Ph.D., VP & General Manager

		
	 Supplier:
	  	 HyClone Laboratories, Inc.
 925
West 1800 South
 Logan, UT 84321

Attention: Lynn R. Quilter, President

 or to such other address as one party may notify the other as provided in writing herein. 
 8.07 Waiver. A waiver by either party of a breach of any of the terms of this Agreement by the other party shall not be deemed a waiver of any subsequent breach of the terms of this Agreement. 

8.08 Governing Law. This Agreement is to be governed by and construed in accordance with Utah law, including all applicable provisions of
the Uniform Commercial Code, but excluding its conflicts of laws rules. If any provision of this Agreement is deemed invalid or unenforceable by a court of competent jurisdiction, such invalidity or enforceability shall not affect or limit the
validity or enforceability of any other provision hereof. 
 8.09 Specific Performance. Both parties shall be entitled to
equitable relief, including injunctive relief and specific performance. Such remedy shall not be the exclusive remedy for any breach of this Agreement, but shall be in addition to all other remedies available at law or equity. 

8.10 Counterparts. This Agreement may be executed in any number of counterparts, each of which once so executed and delivered shall be
deemed an original, but all of which shall constitute but one and the same Agreement. All headings and captions are inserted by 

 
convenience of reference only and shall not affect the meaning or interpretation of any provision hereof. 
 The parties have executed this Agreement as of the date first above written. 
  

									
	ADVANCED BIOHEALING, INC.	 		 	HYCLONE LABORATORIES, INC.
					
	By:	 	/s/ Gerald F. Vovis	 		 	By:	 	/s/ Craig Jack
		 	Gerald F. Vovis, Ph.D	 		 		 	Craig Jack
	Title:	 	General Manager and Vice President	 		 		 	President

									
					
	Date:	 	January 10, 2007	 		 	Date:	 	January 25, 2007

  

 
  
  

 

 Exhibits to Supply Agreement 

 

			
		
	Exhibit A:	  	Description and Specifications for Materials
		
	Exhibit B:	  	Prices for Materials

 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Exhibit
A 
 Standard Materials 
 HyClone # SH30081.02 [***]. 
 ABH # GR0001 

Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). 

Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 HyClone #
SH30070.03 [***] Serum. 
 ABH # GR0035 
 Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment
samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). [***]. 
 Specifications:

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Hemoglobin: [***]. 

	 	6.	Sterility: [***]. 

	 	7.	Virus & Mycoplasma: [***]. 

	 	8.	Growth Promotion: [***]. 

 HyClone #
SH30072.04 Media, Serum, [***]. 
 ABH # 10184 
 Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment
samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). [***]. 
 ***Certain information on this page
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Hemoglobin: [***]. 

	 	6.	Sterility: [***]. 

	 	7.	Virus & Mycoplasma: [***]. 

	 	8.	Growth Promotion: [***]. 

 HyClone #
SH30238.01 [***]. 
 ABH # GR0007 
 Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment
samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Endotoxin: [***]mL. 

	 	4.	Sterility: [***]. 

 HyClone SH30238.02
[***] 
 ABH # 11463 

Shipping Temperature: [***]. 
 Special Instructions: [***] bottles will be required for ABH pre-shipment qualification testing. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Endotoxin: [***]. 

	 	4.	Sterility: [***]. 

 HyClone #
SH30034.01 [***]. 
 ABH # GR0006 
 Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment
samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

 ***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 Page 2

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 Hyclone #
SH30264.02 [***]. 
 ABH # GR0003 
 Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment
samples will be required for ABH lot qualification testing. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 HyClone #
SH30028.03 [***]. 
 ABH # GR0004 
 Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment
samples will be required for ABH lot qualification testing. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 HyClone #
SH30651.01 Bag, [***]. 
 ABH # 10197 
 Shipping Temperature: [***]. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

 HyClone
# SH30651.02 Bag, [***]. 
 ABH # 11381 
 Shipping Temperature: [***]. 
 Specifications: 

	 	1.	Physical Appearance: [***] 

 ***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 Page 3

 [***]. 
 HyClone # SH30221.25 [***] in [***] bag. 
 ABH # 11125 

Shipping Temperature: [***]. 
 Specifications: [***]. 
 ***Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 Page 4

 Custom Materials 
 HyClone # SH3A1253.01 [***]in a [***] bag. 
 ABH # GR0108 

Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). 

Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 HyClone #
SH3A1253.06 [***], supplied [***] in a [***] bag. 
 ABH # 11424 

Shipping Temperature: [***]. 
 Special Instructions: [***] bags will be required for ABH pre-shipment qualification testing and vendor lot retain samples (ship pre-shipment samples [***]). 

Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 HyClone #
SH3A1256.01 Media, [***], supplied in [***] bag. 
 ABH # GR0119 

Shipping Temperature: [***]. 
 Special Instructions: [***] pre-shipment samples are required for ABH qualification testing. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 ***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 Page 5

 HyClone # SH3A1256.03 [***], Supplied in [***] barrel. 

ABH # 11267 
 Shipping
Temperature: [***]. 
 Special Instructions: [***] pre-shipment samples are required for ABH qualification testing.

 Specifications: 

	 	1.	Sterility: [***]. 

	 	2.	pH: [***]. 

	 	3.	Endotoxin: [***]. 

	 	4.	Osmolality: [***]. 

 HyClone #
SH3A1256.05 Media, [***], supplied [***] in a [***] bag. 
 ABH # 11423 

Shipping Temperature: [***]. 
 Special Instructions: [***] bags will be required for ABH pre-shipment qualification testing and vendor lot retain samples. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

 HyClone #
SH3A1257.01 Media, [***], supplied in [***] bag. 
 ABH # 10006 

Shipping Temperature: [***]. 
 Special Instructions: [***] bags will be required for ABH pre-shipment qualification testing and vendor lot retain samples. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Osmolality: [***]. 

	 	4.	Endotoxin: [***]. 

	 	5.	Sterility: [***]. 

	 	6.	Fill Volume Range: [***]. 

 HyClone #
SH3A793.03 [***], supplied in a [***] PETE bottle. 
 ABH # 10664 

Shipping Temperature: [***]. 
 ***Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  
 Page 6

 Special Instructions: [***] pre-shipment samples will be required for ABH lot
qualification testing (ship pre-shipment samples [***]). [***]. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	Sterility Test (USP): [***]. 

	 	3.	pH: [***]. 

	 	4.	[***]. 

	 	5.	[***]. 

 HyClone # SH3A793.01
[***] in a [***] bag. 
 ABH # 10652 
 Shipping Temperature: [***]. 
 Special Instructions: [***]pre-shipment
samples will be required for ABH lot qualification testing (ship pre-shipment samples [***]). [***]. 
 Specifications:

	 	1.	Physical Appearance: [***]. 

	 	2.	Sterility Test (USP): [***]. 

	 	3.	pH: [***]. 

	 	4.	[***]. 

	 	5.	[***]. 

 HyClone # SH3A793.07 [***]
HyClone # SH20622, [***], Supplied [***] in a [***] bag per HyClone part number SH2B0564. 
 ABH # 11434 

Shipping Temperature: [***]. 
 Special Instructions: [***]pre-shipment bags will be required for ABH lot qualification testing (ship pre-shipment samples [***]). [***]. 

Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	pH: [***]. 

	 	3.	Growth Promotion: [***]. 

	 	4.	Mycoplasma: [***]. 

 ***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 Page 7

 HyClone # SH3A427.01 Bag, 4 Port, [***] Reservoir. 

ABH # 10185 
 Shipping
Temperature: [***]. 
 Specifications: 

	 	1.	Physical Appearance: [***]. 

	 	2.	Sterility: [***]. 

	 	3.	[***]. 

	 	4.	[***]. 

 ***Certain information on this
page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 Page 8

 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

							
	QUOTE NUMBER	 	QUOTE DATE	 	EXPIRATION DATE	 	 925 West 1800 South

Logan, Utah 84321

	Advanced BioHealing40561CM0648	 	18-Jan-11	 	31-Dec-11	 

  

									
	Customer Information	  		  	Sales Representative Information	  	For Inquiries on This Sales Order
	Advanced BioHealing	  		  	Maureen Caton	  	Contact:	  	Maureen Caton
		  		  	 	  	Phone: 	  	[***]
	Phone	  		  	Phone [***]	  	Fax: 	  	[***]
	Fax	  		  	Fax [***]	  	Email 	  	[***]
		  		  	 	  	Terms and Conditions are available upon request 

 

																	
	Item	  	 	QUANTITY	  	  	 	UOM	  	  	DESCRIPTION	  	PRICE/UNIT
	  	        To        	 	  	        From        
	 	  	  	  	  
	 	 	 	 	 	 
	Serum	  			 	  			 	  			 	  	 	  	 
	SH30070.03	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# GR0035	  	[***]
	SH30072.04	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] Serum, [***] bottle, ABH# 10184	  	[***]
	 	 	 	 	 	 
	Media	  			 	  			 	  			 	  	 	  	 
	SH30028.03	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# GR0004	  	[***]
	SH30034.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# GR0006	  	[***]
	SH30034.02	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# X-11464	  	[***]
	SH30081.02	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# GR0001	  	[***]
	SH30238.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***], ABH# GR0007	  	[***]
	SH30238.02	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***], ABH# X-11463	  	[***]
	SH30264.02	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# GR0003	  	[***]
	SH3A1253.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bags, ABH# GR0108	  	[***]
	SH3A1253.06	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bags, ABH# X-11424	  	[***]
	SH3A1256.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bag, ABH# GR0119	  	[***]
	SH3A1256.05	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bag, ABH# X-11423	  	[***]
	SH3A1257.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bag, ABH# 10006	  	[***]
	SH3A793.03	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bottle, ABH# 10664	  	[***]
	SH3A793.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bag, ABH# 10652	  	[***]
	SH3A793.07	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	[***] bag with [***] fill, ABH# X-11434	  	[***]
	 	 	 	 	 	 
	BPCs/ Bags	  			 	  			 	  			 	  	 	  	 
	SH30651.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	Standard [***] bag, ABH# 10197	  	[***]
	SH30651.02	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	Standard [***] bag, ABH# X-11381	  	[***]
	SH3A427.01	  	 	[***]	  	  	 	[***]	  	  	 	EA	  	  	Custom [***] bag, ABH# 10185	  	[***]
	Comments	  	 	 	 	  	 	 	 	  	 	 	 	  	 	  	 

 ***Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]